MedTrace Logo

Down-regulated Hormonally Controlled Cycles for Vitrification-warmed Blastocyst Transfers

NCT02238431 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2016-05-26

No results posted yet for this study

Summary

Currently all patients that have freeze-all ICSI treatment cycles have the start of their FET cycle scheduled with the use of OCP. While an excellent pregnancy rate (75%) for the patients that have a blastocyst transfer has been maintained over time, 15% of started FET cycles are being cancelled because of premature luteinization, and the treatment (to transfer) takes approximately 89 days. The use of a Lucrin depot may reduce the number of cycles cancelled and reduce the treatment time to approximately 69 days. The use of no drugs and allowing the normal menstrual cycle to determine the time to start the FET cycle may suit some patients. Whether these benefits can be obtained while still maintaining the current FET pregnancy rate will be the main focus of the trial.

Conditions

  • Pregnancy

Interventions

DRUG

Lucrin depot

scheduling the start of the artificial cycle and hormone down regulation during the artificial cycle

DRUG

OCP

to schedule the start of the artificial cycle

OTHER

Natural

to use the normal menstrual period to schedule treatment start

Sponsors & Collaborators

  • Antalya IVF

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
42 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2016-05-31
Completion
2016-06-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02238431 on ClinicalTrials.gov